CD274 and small cell lung carcinoma: IMpower133 and CASPIAN, randomized phase III clinical trials, showed that the addition of a programmed cell death ligand 1 (PD-L1) antibody to chemotherapy benefited the overall survival of ES-SCLC patients; however, in the BM subgroup, the patients taking ICIs did not exhibit survival superiority.